SUBSCRIPTIONS

- Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, et al; AVANOVA investigators. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019;20:1409-19. https://doi.org/10.1016/S1470-2045(19)30515-7
- González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391-402. https://doi.org/10.1056/NEJMoa1910962

The Transparency Score is explained in New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.

At the time the comment was prepared, information about this drug was available on the websites of the Food and Drug Administration in the USA, and the European Medicines Agency.

A:

ANSWERS TO SELF-TEST QUESTIONS

1 True 2 True

3 True 4 False

5 False

Correction

The safety of commonly used vitamins and minerals [Correction]

Aust Prescr 2021;44:209

First published 5 November 2021

https://doi.org/10.18773/austprescr.2021.060

The article on the safety of vitamins and minerals (Aust Prescr 2021;44:119-23) has been corrected. View corrected article.

In the 'Vitamin A' section of the main text, it incorrectly states that toxicity can occur with regular ingestion of more than 100,000 IU daily. This should read "Vitamin A toxicity can occur with regular ingestion of more than 10,000 IU daily". The information on vitamin A toxicity in Box 1 is correct.

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor

Australian Prescriber GPO Box 266 Canberra, ACT 2600

Telephone +61 2 8217 8700

Email info@australianprescriber.com

Website nps.org.au/australian-prescriber

Twitter @AustPrescriber

SUBSCRIPTIONS

Australian Prescriber is published every two months online. All content is accessible free of charge in full text at nps.org.au/ australian-prescriber. New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at nps.org.au/australian-prescriber

For free copies of the Anaphylaxis wallchart and Switching-antidepressants poster, order online at www.nps.org.au/order#for-health-professionals © 2021 NPS MedicineWise ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.